Drug resistance and treatment failure in leishmaniasis: A 21st century challenge

Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently needed on a global basis because treatment failure is an increasing problem. Drug resistance is a fundamental determinant of treatment failure, although other factors also contribute to this phenomenon, including th...

ver descrição completa

Detalhes bibliográficos
Autores: Ponte-Sucre, Alicia, Gamarro, Francisco, Dujardin, J. C., Barrett, Michael P., López-Vélez, Rogelio, García-Hernández, Raquel, Pountain, Andrew W., Mwenechanya, Roy, Papadopoulou, Barbara
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/167426
Acesso em linha:http://hdl.handle.net/10261/167426
Access Level:acceso abierto
Palavra-chave:AMPHOTERICIN-B RESISTANCE
PROTOZOAN PARASITE LEISHMANIA
ABC-TRANSPORTER MRPA
VISCERAL LEISHMANIASIS
DONOVANI PROMASTIGOTES
Cutaneous leishmaniasis
MILTEFOSINE RESISTANCE
Antimony-resistant
MEGLUMINE ANTIMONIATE
SODIUM STIBOGLUCONATE
id ES_bce4a4775ffecbc2f9bba741735b9776
oai_identifier_str oai:digital.csic.es:10261/167426
network_acronym_str ES
network_name_str España
repository_id_str
spelling Drug resistance and treatment failure in leishmaniasis: A 21st century challengePonte-Sucre, AliciaGamarro, FranciscoDujardin, J. C.Barrett, Michael P.López-Vélez, RogelioGarcía-Hernández, RaquelPountain, Andrew W.Mwenechanya, RoyPapadopoulou, BarbaraAMPHOTERICIN-B RESISTANCEPROTOZOAN PARASITE LEISHMANIAABC-TRANSPORTER MRPAVISCERAL LEISHMANIASISDONOVANI PROMASTIGOTESCutaneous leishmaniasisMILTEFOSINE RESISTANCEAntimony-resistantMEGLUMINE ANTIMONIATESODIUM STIBOGLUCONATEReevaluation of treatment guidelines for Old and New World leishmaniasis is urgently needed on a global basis because treatment failure is an increasing problem. Drug resistance is a fundamental determinant of treatment failure, although other factors also contribute to this phenomenon, including the global HIV/AIDS epidemic with its accompanying impact on the immune system. Pentavalent antimonials have been used successfully worldwide for the treatment of leishmaniasis since the first half of the 20th century, but the last 10 to 20 years have witnessed an increase in clinical resistance, e.g., in North Bihar in India. In this review, we discuss the meaning of “resistance” related to leishmaniasis and discuss its molecular epidemiology, particularly for Leishmania donovani that causes visceral leishmaniasis. We also discuss how resistance can affect drug combination therapies. Molecular mechanisms known to contribute to resistance to antimonials, amphotericin B, and miltefosine are also outlined.Research reported in this publication was supported by the Canadian Institutes of Health Research operating grant MOP-12182 awarded to BP; the Spanish Grant Proyecto de Excelencia, Junta de Andalucía Ref. CTS-7282 awarded to FG; the Spanish Grant SAF2015-68042-R awarded to FG; the Wellcome Trust (104111/Z/14/Z) awarded to MPB; and the Alexander von Humboldt Foundation, Germany awarded to APS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Peer reviewedPublic Library of ScienceCanadian Institutes of Health ResearchJunta de AndalucíaWellcome TrustAlexander von Humboldt FoundationMinisterio de Economía y Competitividad (España)Pountain, Andrew W.[0000-0001-9651-5145]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]201820182017info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionhttp://hdl.handle.net/10261/167426reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Inglés#PLACEHOLDER_PARENT_METADATA_VALUE#info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/SAF2015-68042-Rhttp://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006052Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/1674262026-05-22T06:33:51Z
dc.title.none.fl_str_mv Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
title Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
spellingShingle Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
Ponte-Sucre, Alicia
AMPHOTERICIN-B RESISTANCE
PROTOZOAN PARASITE LEISHMANIA
ABC-TRANSPORTER MRPA
VISCERAL LEISHMANIASIS
DONOVANI PROMASTIGOTES
Cutaneous leishmaniasis
MILTEFOSINE RESISTANCE
Antimony-resistant
MEGLUMINE ANTIMONIATE
SODIUM STIBOGLUCONATE
title_short Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
title_full Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
title_fullStr Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
title_full_unstemmed Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
title_sort Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
dc.creator.none.fl_str_mv Ponte-Sucre, Alicia
Gamarro, Francisco
Dujardin, J. C.
Barrett, Michael P.
López-Vélez, Rogelio
García-Hernández, Raquel
Pountain, Andrew W.
Mwenechanya, Roy
Papadopoulou, Barbara
author Ponte-Sucre, Alicia
author_facet Ponte-Sucre, Alicia
Gamarro, Francisco
Dujardin, J. C.
Barrett, Michael P.
López-Vélez, Rogelio
García-Hernández, Raquel
Pountain, Andrew W.
Mwenechanya, Roy
Papadopoulou, Barbara
author_role author
author2 Gamarro, Francisco
Dujardin, J. C.
Barrett, Michael P.
López-Vélez, Rogelio
García-Hernández, Raquel
Pountain, Andrew W.
Mwenechanya, Roy
Papadopoulou, Barbara
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Canadian Institutes of Health Research
Junta de Andalucía
Wellcome Trust
Alexander von Humboldt Foundation
Ministerio de Economía y Competitividad (España)
Pountain, Andrew W.[0000-0001-9651-5145]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv AMPHOTERICIN-B RESISTANCE
PROTOZOAN PARASITE LEISHMANIA
ABC-TRANSPORTER MRPA
VISCERAL LEISHMANIASIS
DONOVANI PROMASTIGOTES
Cutaneous leishmaniasis
MILTEFOSINE RESISTANCE
Antimony-resistant
MEGLUMINE ANTIMONIATE
SODIUM STIBOGLUCONATE
topic AMPHOTERICIN-B RESISTANCE
PROTOZOAN PARASITE LEISHMANIA
ABC-TRANSPORTER MRPA
VISCERAL LEISHMANIASIS
DONOVANI PROMASTIGOTES
Cutaneous leishmaniasis
MILTEFOSINE RESISTANCE
Antimony-resistant
MEGLUMINE ANTIMONIATE
SODIUM STIBOGLUCONATE
description Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently needed on a global basis because treatment failure is an increasing problem. Drug resistance is a fundamental determinant of treatment failure, although other factors also contribute to this phenomenon, including the global HIV/AIDS epidemic with its accompanying impact on the immune system. Pentavalent antimonials have been used successfully worldwide for the treatment of leishmaniasis since the first half of the 20th century, but the last 10 to 20 years have witnessed an increase in clinical resistance, e.g., in North Bihar in India. In this review, we discuss the meaning of “resistance” related to leishmaniasis and discuss its molecular epidemiology, particularly for Leishmania donovani that causes visceral leishmaniasis. We also discuss how resistance can affect drug combination therapies. Molecular mechanisms known to contribute to resistance to antimonials, amphotericin B, and miltefosine are also outlined.
publishDate 2017
dc.date.none.fl_str_mv 2017
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/167426
url http://hdl.handle.net/10261/167426
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv #PLACEHOLDER_PARENT_METADATA_VALUE#
info:eu-repo/grantAgreement/MINECO/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/SAF2015-68042-R
http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006052
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Public Library of Science
publisher.none.fl_str_mv Public Library of Science
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418154061463552
score 15,812429

Registos relacionados